

# Clinical trial of electrical stimulation of leg muscles as a new way to prevent deep vein thrombosis and pulmonary embolism after stroke

<b>Submission date</b> 08/09/2022	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 23/09/2022	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 20/08/2025	<b>Condition category</b> Circulatory System	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Venous thromboembolism (VTE) is a disabling and potentially fatal outcome that may be acquired in patients who are immobilised after an acute stroke. The standard treatment to prevent the development of VTE is to give anticoagulation medication. However, this is not recommended in the UK for patients who have had a stroke. Instead, the recommended treatment is intermittent pneumatic compression (IPC), where cuffs are placed around the lower legs and filled with air to help squeeze the legs and induce blood flow. However, not all patients are able to receive or tolerate IPC treatment. Another treatment which has shown promising results to prevent VTE in immobile patients after stroke is a medical device called the geko™ device. The geko™ device is a CE-marked medical device, which means the manufacturer has checked that the device complies with the essential safety and performance requirements for its intended use, which is to increase blood circulation to help prevent VTE. The aim of this study is to determine if the geko™ device is more effective at preventing VTE in immobile acute stroke patients, than the current IPC standard of care treatment.

### Who can participate?

Immobile acute stroke patients aged 18 years or older

### What does the study involve?

Participants will be allocated to one of two groups, with an equal chance of being in either group (like tossing a coin). One group of participants will be treated with the geko™ device, a small, self-adhesive electrostimulation device, which stimulates a nerve in the lower leg that causes the calf muscles to contract. This will be applied for 24 hours daily, until the participant recovers mobility, is discharged, or for a maximum of 30 days. The other group of participants will receive the standard of care IPC treatment, until the participant recovers mobility, is discharged, or for a maximum of 30 days. Compression Doppler imaging, which is a special type of ultrasound imaging, will be carried out to assess the participants for deep vein thrombosis (DVT) any time there is a clinical suspicion of DVT, and in addition at 7 days after randomisation or at discharge

if earlier (optional compression Doppler) and/or 14 days after randomisation (mandatory visit). If indicated clinically, pulmonary embolism will be assessed by ventilation-perfusion scan or by computer tomography pulmonary angiogram (CTPA). Additional information including the NIH stroke score and adverse event information will be collected at 7 days (if practical) and 14 days after randomisation. At 14 days after randomisation, a device acceptability questionnaire and collection of other relevant information (e.g. final diagnosis, number of days in intensive care) will also be carried out. At 30 days after randomisation, information including incidences of symptomatic DVTs, PEs and antiplatelet/anticoagulation medication will be collected from medical notes. A final follow-up will be conducted 90 days after randomisation with the participant by phone (unless requested otherwise), to follow up on the participant's vital status, any DVT/PE diagnoses, as well as collecting information on the participant's health status and functional outcomes.

**What are the possible benefits and risks of participating?**

There are no guarantees that there are any direct benefits to the participant by participating in this study. However, the results of the study will help inform the recommended preventative treatment of venous thromboembolism for future immobile acute stroke patients, with the aim to improve recovery for patients. Participants will also contribute to the knowledge pool on the safety and performance of the geko™ device, which may also help improve treatment for future patients. There are no expected risks or disadvantages to participating in the study. Whichever group the participant is allocated to, their care will be overseen by their healthcare team. Some patients may develop a rash if they are allergic to the materials used in the study devices.

**Where is the study run from?**

Keele University (UK)

**When is the study starting and how long is it expected to run for?**

February 2021 to November 2025

**Who is funding the study?**

The National Institute for Health and Care Research (NIHR) (UK)

**Who is the main contact?**

Prof. Christine Roffe

[christine.roffe@uhnm.nhs.uk](mailto:christine.roffe@uhnm.nhs.uk)

## Contact information

### Type(s)

Principal investigator

### Contact name

Prof Christine Roffe

### ORCID ID

<https://orcid.org/0000-0002-5259-6649>

### Contact details

Guy Hilton Research Building,  
Keele University  
1 Thornburrow Drive

Stoke-on-Trent  
United Kingdom  
ST4 7QB  
+44 (0)1782671655  
christine.roffe@uhnm.nhs.uk

**Type(s)**

Public

**Contact name**

Dr Wing To

**Contact details**

Firstkind Limited  
Hawk House  
Gomm Road  
High Wycombe  
United Kingdom  
HP13 7DL  
+44 (0)7827612109  
wing.to@firstkindmedical.com

**Type(s)**

Scientific

**Contact name**

Dr Kieron Day

**Contact details**

Firstkind Limited  
Hawk House  
Gomm Road  
High Wycombe  
United Kingdom  
HP13 7DL  
+44 (0)7921106253  
kieron.day@firstkindmedical.com

## **Additional identifiers**

**Integrated Research Application System (IRAS)**

315387

**ClinicalTrials.gov (NCT)**

NCT05476913

**Protocol serial number**

FSK-VTE-001, IRAS 315387

## **Study information**

## **Scientific Title**

A randomised controlled trial of the effectiveness of intermittent surface neuromuscular stimulation using the geko™ device compared with intermittent pneumatic compression to prevent venous thromboembolism in immobile acute stroke patients

## **Study objectives**

The geko™ neuromuscular electrical stimulation (NMES) device is more effective than intermittent pneumatic compression (IPC) at preventing venous thromboembolism (VTE) events in patients with acute stroke.

## **Ethics approval required**

Ethics approval required

## **Ethics approval(s)**

approved 21/02/2023, North West - Greater Manchester South Research Ethics Committee (3rd Floor, Barlow House, 4 Minshull Street, Manchester, M1 3DZ, United Kingdom; +44 (0)208 104 8051; gmsouth.rec@hra.nhs.uk), ref: 23/NW/0001

## **Study design**

Prospective multicentre randomized controlled trial, single-blinded to the primary outcome

## **Primary study design**

Interventional

## **Study type(s)**

Prevention

## **Health condition(s) or problem(s) studied**

Prevention of venous thromboembolism in acute stroke patients

## **Interventions**

Current interventions as of 17/03/2025:

This study is looking at venous thromboembolism (VTE) prevention in patients suffering an acute stroke.

The Investigational arm will receive the geko™ device, a self-adhesive neuromuscular stimulator. This will be compared to the control arm using Intermittent Pneumatic Compression (IPC) as standard of care.

Participants will be allocated to a treatment group via an online randomisation tool, applied centrally across the study sites. After randomisation, the participant will immediately receive their allocated treatment for 24 hours daily, until they can walk again without help, are discharged into the community, for a maximum of 30 days or other criteria are met including e.g. primary outcome has been met (VTE condition) and treatment dose / full dose anticoagulation treatment administered.

Previous interventions:

This study is looking at venous thromboembolism (VTE) prevention in patients suffering an acute stroke.

The Investigational arm will receive the geko™ device, a self-adhesive neuromuscular stimulator. This will be compared to the control arm using Intermittent Pneumatic Compression (IPC) as standard of care.

Participants will be allocated to a treatment group via an online randomisation tool, applied centrally across the study sites. After randomisation, the participant will immediately receive their allocated treatment for 24 hours daily, until they can walk again without help, are discharged, or for a maximum of 30 days.

## **Intervention Type**

Device

## **Phase**

Not Applicable

## **Drug/device/biological/vaccine name(s)**

geko™ device

## **Primary outcome(s)**

Current primary outcome measure as of 17/05/2024:

Frequency of any symptomatic or asymptomatic Deep Vein Thrombosis (DVT) in the calf, popliteal or femoral veins or any Pulmonary Embolism (PE) within 30 days of randomisation. DVT will be diagnosed using compression Doppler imaging, conducted any time there is a clinical suspicion of DVT and at 7 days (optional) and 14 days (mandatory) after randomisation.

Previous primary outcome measure:

Frequency of any symptomatic or asymptomatic Deep Vein Thrombosis (DVT) in the calf, popliteal or femoral veins or any Pulmonary Embolism (PE) within 30 days of randomisation. DVT will be diagnosed using whole leg compression Doppler imaging, conducted any time there is a clinical suspicion of DVT and at 7 days and 14 days after randomisation, or at patient discharge if the patient recovers within a 3-day window of these follow-up timepoints.

## **Key secondary outcome(s)**

Current secondary outcome measure as of 17/05/2024:

1. Patient tolerability to either study device assessed using the Device Acceptability Questionnaire at 14 days after randomisation.
2. Device effectiveness based on the frequency of patient death for any cause, confirmed fatal or non-fatal PE, any (symptomatic or asymptomatic) above knee DVT and a combination of these outcomes at 30 days after randomisation.
3. Device effectiveness based on the frequency of any symptomatic or asymptomatic DVT in popliteal or femoral veins and symptomatic calf vein DVT at 30 days after randomisation.
4. Leg pain level measured using a Numerical Rating Score (NRS) at 90 days after randomisation.
5. Health-related quality of life measured using EQ-5D-5L, at baseline if possible and at 90 days after randomisation.
6. Patient survival at 90 days after randomisation.
7. The frequency of venous thromboembolism (any symptomatic or asymptomatic DVT or PE) occurring between randomisation and 90 days after randomisation.
8. Device safety assessed by documenting adverse event assessments up to 30 days after randomisation or at patient discharge if earlier.
9. Stroke-related neurologic deficit assessed using the NIH stroke scale (NIHSS) at 7 days and 14 days after randomisation.

Previous secondary outcome measure:

1. Patient tolerability to either study device assessed using Device Acceptability Questionnaire at 30 days after randomisation or at patient discharge if earlier

2. Device effectiveness based on the frequency of patient death for any cause, confirmed fatal or non-fatal PE, any (symptomatic or asymptomatic) above knee DVT and a combination of these outcomes at 30 days after randomisation
3. Device effectiveness based on the frequency of any symptomatic or asymptomatic DVT in popliteal or femoral veins and symptomatic calf vein DVT at 30 days after randomisation
4. Leg pain level measured using a Numerical Rating Score (NRS) at 90 days after randomisation
5. Health-related quality of life measured using EQ-5D-5L, at baseline if possible and at 90 days after randomisation
6. Patient survival at 90 days after randomisation
7. The frequency of venous thromboembolism (any symptomatic or asymptomatic DVT or PE) occurring between randomisation and 90 days after randomisation
8. Device safety assessed by documenting adverse event assessments at 30 days after randomisation or at patient discharge if earlier
9. Stroke-related neurologic deficit assessed using the NIH stroke scale (NIHSS) at 7 days, 14 days and 30 days after randomisation or at patient discharge if the patient recovers earlier

**Completion date**

30/11/2025

## Eligibility

**Key inclusion criteria**

Current inclusion criteria as of 20/08/2025:

1. Aged 18 years or older
2. Clinical diagnosis of acute stroke (WHO criteria)
3. Within 72 hours of symptom onset
4. Not able to get up from a chair/out of bed and walk to the toilet without the help of another person

Previous inclusion criteria:

1. Aged 18 years or older
2. Clinical diagnosis of acute stroke (WHO criteria)
3. Within 36 hours of symptom onset
4. Not able to get up from a chair/out of bed and walk to the toilet without the help of another person

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Sex**

All

**Total final enrolment**

230

**Key exclusion criteria**

1. Inability to gain consent from the patient, or a declaration from a Personal Consultee or Nominated Consultee
2. Unwitnessed onset with a long lie on the floor before admission
3. Clinically apparent deep vein thrombosis at screening
4. Patient is expected to require palliative care within 14 days
5. Patient does not live in the local catchment area and is expected to be transferred to their local hospital for ongoing care
6. Patient has recently been involved in or is currently involved in a clinical trial for either a medical device or medicinal product, within the past 3 months, with the exception: if co-enrolment is not considered to impact adverse events or outcomes in the opinion of the Chief Investigator
7. Contraindications for the use of the geko™ device:
  - 7.1. Allergy to hydrogel constituents
8. Contraindications to IPC:
  - 8.1. Severe peripheral vascular disease
  - 8.2. Large leg ulcers requiring extensive bandaging (small ulcers or skin breaks with flat coverings are not an exclusion)
  - 8.3. Severe oedema
  - 8.4. Leg deformities making appropriate fitting impossible
9. Uncontrolled congestive cardiac failure
10. Pregnancy or breastfeeding
11. Single or double leg amputations

**Date of first enrolment**

06/07/2023

**Date of final enrolment**

30/06/2025

**Locations****Countries of recruitment**

United Kingdom

England

**Study participating centre**

**Royal Stoke University Hospital**

Newcastle Road

Stoke-on-trent

United Kingdom

ST4 6QG

**Study participating centre**  
**Royal United Hospitals Bath NHS Foundation Trust**  
Combe Park  
Bath  
United Kingdom  
BA1 3NG

**Study participating centre**  
**Whiston Hospital**  
St. Helens & Knowsley Hospital  
Warrington Road  
Prescot  
United Kingdom  
L35 5DR

**Study participating centre**  
**Fairfield General Hospital**  
Fairfield General Hospital  
Rochdale Old Road  
Bury  
United Kingdom  
BL9 7TD

**Study participating centre**  
**West Suffolk Hospital**  
Hardwick Ln  
Bury Saint Edmunds  
United Kingdom  
IP29 5DN

**Study participating centre**  
**Countess of Chester Hospital**  
Countess of Chester Health Park  
Liverpool Road  
Chester  
United Kingdom  
CH2 1UL

**Study participating centre**  
**Royal Bournemouth General Hospital**  
Castle Lane East



Bournemouth  
United Kingdom  
BH7 7DW

**Study participating centre**  
**Addenbrookes Hospital**  
Hills Road  
Cambridge  
United Kingdom  
CB2 0QQ

**Study participating centre**  
**Queens Medical Centre**  
Derby Road  
Nottingham  
United Kingdom  
NG7 2UH

**Study participating centre**  
**Northwick Park Hospital**  
Watford Road  
Harrow  
United Kingdom  
HA1 3UJ

**Study participating centre**  
**Milton Keynes University Hospital**  
Standing Way  
Eaglestone  
Milton Keynes  
United Kingdom  
MK6 5LD

**Study participating centre**  
**New Cross Hospital**  
Wolverhampton Road  
Heath Town  
Wolverhampton  
United Kingdom  
WV10 0QP

**Study participating centre**  
**Salford Royal Hospital**  
Stott Lane  
Eccles  
Salford  
United Kingdom  
M6 8HD

**Study participating centre**  
**Yeovil District Hospital**  
Higher Kingston  
Yeovil  
United Kingdom  
BA21 4AT

**Study participating centre**  
**Stepping Hill Hospital**  
Poplar Grove  
Stockport  
United Kingdom  
SK2 7JE

**Study participating centre**  
**Kings College Hospital**  
Mapother House  
De Crespigny Park  
Denmark Hill  
London  
United Kingdom  
SE5 8AB

**Study participating centre**  
**Queen Elizabeth Hospital**  
Mindelsohn Way  
Edgbaston  
Birmingham  
United Kingdom  
B15 2GW

**Study participating centre**  
Kent and Canterbury Hospitals NHS Trust  
Ethelbert Road  
Canterbury  
United Kingdom  
CT1 3NG

## Sponsor information

**Organisation**  
Firstkind Limited

## Funder(s)

**Funder type**  
Government

**Funder Name**  
National Institute for Health and Care Research

**Alternative Name(s)**  
National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

**Funding Body Type**  
Government organisation

**Funding Body Subtype**  
National government

**Location**  
United Kingdom

## Results and Publications

### Individual participant data (IPD) sharing plan

The study dataset generated during and/or analysed during the current study will be stored in a non-publicly available database (electronic data capture system). The database will be hosted by Medrio electronic data capture (EDC). This study dataset will be shared with Dr Martyn Lewis from the Clinical Trials Unit at Keele University, for analysis and generation of data summaries. This data may also be analysed and summarised by the study Sponsor, Firstkind Ltd. The (de-identified) compression Doppler images will be stored in an encrypted, external hard drive

provided by the Sponsor for study purposes. These will then be transferred to a secure server in the UK. 5% of the compression Doppler images will be analysed by an independent sonographer for quality assurance purposes. Patients will be informed via the study Patient Information Sheet regarding the sharing of these de-identified datasets with the Sponsor and with the independent qualified experts.

The datasets generated during and/or analysed during the current study are/will be available upon request from Prof Christine Roffe (christine.roffe@uhnm.nhs.uk) after publication.

### **IPD sharing plan summary**

Stored in non-publicly available repository, Available on request

### **Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Participant information sheet</a>	Participant information sheet	11/11/2025	11/11/2025	No	Yes